Okuda Katsuhiro, Tatematsu Tsutomu, Yano Motoki, Nakamae Katsumi, Yamada Takeshi, Kasugai Toshio, Nishida Tsutomu, Sano Masaaki, Moriyama Satoru, Haneda Hiroshi, Kawano Osamu, Sakane Tadashi, Oda Risa, Watanabe Takuya, Nakanishi Ryoichi
Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
Department of Surgery, Aichi Medical University, Nagakute, Aichi 480-1195, Japan.
Mol Clin Oncol. 2018 Jul;9(1):21-29. doi: 10.3892/mco.2018.1619. Epub 2018 May 4.
Previous studies have reported that the expressions of specific proteins may predict the efficacy of chemotherapy agents for non-small cell lung cancer (NSCLC) patients. The present study evaluated the expression of proteins hypothesized to be associated with the effect of chemotherapeutic agents in 38 NSCLC patients with pathological stage II and IIIA. The subjects received carboplatin plus paclitaxel (CP) or S-1 as adjuvant chemotherapy following complete resection. The protein expressions evaluated were those of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phsphoribosyltransferase (OPRT), which were suspected to be associated with the effect of S-1 agents, excision repair cross-complementation group 1 (ERCC1), which was suspected to be associated with the effect of platinum-based agents, and class III β-tubulin (TUBB3), which was suspected to be associated with the effect of taxane-based agents. The positive rate of TS was 55.3% (n=21/38), DPD was 57.9% (n=22/38), OPRT was 42.1% (n=16/38), ERCC1 was 47.4% (n=18/38) and TUBB3 was 44.7% (n=17/38). Among the patients who received S-1 adjuvant chemotherapy, TS-negative cases demonstrated a significantly better disease-free survival than positive cases. Thus, TS protein expression may have been a factor that predicted the effect of S-1 agent as adjuvant chemotherapy.
以往研究报道，特定蛋白质的表达可能预测非小细胞肺癌（NSCLC）患者化疗药物的疗效。本研究评估了38例病理分期为II期和IIIA期的NSCLC患者中，假设与化疗药物疗效相关的蛋白质表达情况。这些受试者在完全切除术后接受了卡铂加紫杉醇（CP）或S-1作为辅助化疗。评估的蛋白质表达包括胸苷酸合成酶（TS）、二氢嘧啶脱氢酶（DPD）和乳清酸磷酸核糖转移酶（OPRT），怀疑它们与S-1药物的疗效相关；切除修复交叉互补组1（ERCC1），怀疑其与铂类药物的疗效相关；以及III类β-微管蛋白（TUBB3），怀疑其与紫杉烷类药物的疗效相关。TS的阳性率为55.3%（n = 21/38），DPD为57.9%（n = 22/38），OPRT为42.1%（n = 16/38），ERCC1为47.4%（n = 18/38），TUBB3为44.7%（n = 17/38）。在接受S-1辅助化疗的患者中，TS阴性病例的无病生存期明显优于阳性病例。因此，TS蛋白表达可能是预测S-1作为辅助化疗药物疗效的一个因素。
